» Articles » PMID: 38736748

Characterization and Efficacy Against Carbapenem-resistant of a Novel Phage from Sewage

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Carbapenem-resistant (CRAB) has become a new threat in recent years, owing to its rapidly increasing resistance to antibiotics and new effective therapies are needed to combat this pathogen. Phage therapy is considered to be the most promising alternative for treating CRAB infections. In this study, a novel phage, Ab_WF01, which can lyse clinical CRAB, was isolated and characterized from hospital sewage. The multiplicity of infection, morphology, one-step growth curve, stability, sensitivity, and lytic activity of the phage were also investigated. The genome of phage Ab_WF01 was 41, 317 bp in size with a GC content of 39.12% and encoded 51 open reading frames (ORFs). tRNA, virulence, and antibiotic resistance genes were not detected in the phage genome. Comparative genomic and phylogenetic analyses suggest that phage Ab_WF01 is a novel species of the genus , subfamily , and family . The results showed that phage Ab_WF01 significantly increased the survival rate of CRAB-infected (from 0% to 70% at 48 h) and mice (from 0% to 60% for 7 days). Moreover, after day 3 post-infection, phage Ab_WF01 reduced inflammatory response, with strongly ameliorated histological damage and bacterial clearance in infected tissue organs (lungs, liver, and spleen) in mouse CRAB infection model. Taken together, these results show that phage Ab_WF01 holds great promise as a potential alternative agent with excellent stability for against CRAB infections.

Citing Articles

Recent insights on phage therapy against multidrug-resistant Acinetobacter baumannii.

Elshamy A, Kamal S, Mahmoud M, Elhasany A, Shady A, Mohamed S AMB Express. 2025; 15(1):44.

PMID: 40072684 PMC: 11904003. DOI: 10.1186/s13568-025-01837-1.


Geographic variation in abundance and diversity of bacteriophages.

Arellano-Maciel D, Hurtado-Ramirez J, Camelo-Valera L, Castillo-Ramirez S, Reyes A, Lopez-Leal G Front Microbiol. 2025; 16:1522711.

PMID: 39935639 PMC: 11813220. DOI: 10.3389/fmicb.2025.1522711.


Bacteriophage and Phage-Encoded Depolymerase Exhibit Antibacterial Activity Against K9-Type in Mouse Sepsis and Burn Skin Infection Models.

Borzilov A, Volozhantsev N, Korobova O, Kolupaeva L, Pereskokova E, Kombarova T Viruses. 2025; 17(1.

PMID: 39861859 PMC: 11768871. DOI: 10.3390/v17010070.

References
1.
Hua Y, Luo T, Yang Y, Dong D, Wang R, Wang Y . Phage Therapy as a Promising New Treatment for Lung Infection Caused by Carbapenem-Resistant in Mice. Front Microbiol. 2018; 8:2659. PMC: 5767256. DOI: 10.3389/fmicb.2017.02659. View

2.
Pu M, Li Y, Han P, Lin W, Geng R, Qu F . Genomic characterization of a new phage BUCT541 against K1-ST23 and efficacy assessment in mouse and larvae. Front Microbiol. 2022; 13:950737. PMC: 9523250. DOI: 10.3389/fmicb.2022.950737. View

3.
Gao L, Ouyang M, Li Y, Zhang H, Zheng X, Li H . Isolation and Characterization of a Lytic Vibriophage OY1 and Its Biocontrol Effects Against spp. Front Microbiol. 2022; 13:830692. PMC: 9022663. DOI: 10.3389/fmicb.2022.830692. View

4.
Chu J, Poh W, Hasnuddin N, Hew E, Dam L, El Sahili A . Novel Phage Lysin Abp013 against . Antibiotics (Basel). 2022; 11(2). PMC: 8868305. DOI: 10.3390/antibiotics11020169. View

5.
Wu N, Dai J, Guo M, Li J, Zhou X, Li F . Pre-optimized phage therapy on secondary infection in four critical COVID-19 patients. Emerg Microbes Infect. 2021; 10(1):612-618. PMC: 8032346. DOI: 10.1080/22221751.2021.1902754. View